Replies to post #247177 on Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

Elite will have exclusivity in these markets:
These will be first in there class no ADF versions to compete with.
Elite will take from the NON ADF market and move it to their exclusive ADF markets.

THX for pointing out the exclusivity Elite will have GL

ELTP

1.)No other Immediate Release ADF labeled opiod exists
----------- SequestOx™ ----------
2.) No other generic ER ADF labeled Oxycodone exists (ELI-201)
3.) No other generic Embeda® exists
4.) No other generic ADF reformulated OxyContin® exists
5.) No other generic Troxyca® exists
6.) No other 24 hour (once per day) oxycodone ELI-216 exists

[NASDAQ2020]

OK so we get 5%, we are still rich, GL

The global opioid market reached $33.924 billion in 2014 and is estimated to have reached $34.89 billion in 2015, data from Persistent Market Research shows. Experts believe the market will reach $42.16 billion by 2021, or a 3.2% compound annual growth rate (CAGR).

The steady rise in the opioid market is being attributed to prescription pain medication and the ease in getting illegal opiate-based drugs. It is estimated at least 9% of the population has misused opioids at one point in their life.

[NASDAQ2020]

Which ever Pharma buys out Elite has a good shot at being THE leader in the ADF pain market.

This is why we continue to get farther and farther from the 52 week low last year.
GL

[snupoled]

Jour,

the bed shook man!

she wants to run!

snupDAWGoled